Aditxt and Evofem amend merger agreement
Aditxt and Evofem amend merger agreement
Aditxt signs second amendment to arrangement agreement with Appili Therapeutics
Aditxt signs agreement to acquire Appili Therapeutics
Aditxt buys Brain Scientific's portfolio of EEG brain monitoring technologies and devices
Aditxt to acquire women’s health company Evofem Biosciences
2.89MUSD
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US0070251097
CUSIP
007025109
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-
Book Value
13.73
Dividend Share
-
Dividend Yield
-
Earnings Share
-25.94
Wall Street Target Price
61.00
EPS Estimate Current Year
-
EPS Estimate Next Year
-
EPS Estimate Current Quarter
0
EPS Estimate Next Quarter
0
Most Recent Quarter
-
Revenue TTM
55,323
Gross Profit TTM
-507,086
EBITDA
-21,396,732
Profit Margin
0.00%
Return On Assets TTM
-46.32%
Return On Equity TTM
-204.37%
Revenue Per Share TTM
0.293
Qtly Revenue Growth YOY
-98.70%
Diluted Eps TTM
-25.94
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
0
Price Sales TTM
53.173
Price Book MRQ
0.1744
Enterprise Value Revenue
117
Enterprise Value EBITDA
0
161.72
3.67%294.50
1.56%100.91
1.47%547.60
0.00%203.85
0.00%319.08
-1.77%542.01
-1.45%564.75
-1.38%459.99
-0.73%80.86
-0.19%